# **International Conference 2023**

November 8 (Wed) - 10 (Fri), 2023 / Lotte Hotel World, Seoul, Korea

www.katrdic.org

Name	JU SANG KIM	
Country	South Korea	(ac)
Organization	Incheon St. Mary's Hospital, The Catholic University of Korea	
Current Position	Clinical Professor	

### **Educational Background**

1999. The College of Medicine, CheonBuk National University. ,M.D. 2007-2011: Ph.D. Department of Internal Medicine, College of Medicine, The Catholic University of Korea

### **Professional Experiences**

1999. Intern, The Catholic Medical Center
2000-2004; Rotating Resident, Internal medicine, The Catholic Medical Center,
2007-2008: Fellowship. Division of Pulmonology & Critical Care Medicine, Incheon/Seoul St. Mary's
Hospital, The Catholic University of Korea
2009~2017: Assistant professor
2018-2023; Clinical Associate professor
2023~current: Clinical Professor

#### **Professional Organizations**

2011-2014 Sub PI. Of PPM program 2014- Current: Head of Central analysis Team, PPM program, Sub PI. Of PPM program 2017-2019, 2013~ Current ; The board member of the TB specialized Committee, KDCA

#### **Main Scientific Publications**

1. Shin AY, Jekarl DW, Kim HW, Ha JH, Ahn JH, Kim JS. Early line-probe assay using DNA specimens in patients with pulmonary TB. Int J Tuberc Lung Dis. 2022;26(6):509-15.

2. Oh JY, Lee SS, Kim HW, Min J, Ko Y, Koo HK, et al. Additional Usefulness of Bronchoscopy in Patients with Initial Microbiologically Negative Pulmonary Tuberculosis: A Retrospective Analysis of a Korean Nationwide Prospective Cohort Study. Infect Drug Resist. 2022;15:1029-37.

3. Mok J, Lee M, Kim DK, Kim JS, Jhun BW, Jo KW, et al. 9 months of delamanid, linezolid, levofloxacin, and pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-END): a multicentre, randomised, open-label phase 2/3 non-inferiority trial in South Korea. Lancet. 2022;400(10362):1522-30.

4. Min J, Ko Y, Kim HW, Koo HK, Oh JY, Jeong YJ, et al. Increased Healthcare Delays in Tuberculosis Patients During the First Wave of COVID-19 Pandemic in Korea: A Nationwide Cross-Sectional Study. J Korean Med Sci. 2022;37(3):e20.

5. Min J, Kim HW, Stagg HR, Rangaka MX, Lipman M, Abubakar I, et al. The cascade of care for latent tuberculosis infection in congregate settings: A national cohort analysis, Korea, 2017-2018. Front Med (Lausanne). 2022;9:927579.

## The 136th Congress of the Korean Academy of Tuberculosis and Respiratory Diseases

# **International Conference 2023**

6.

November 8 (Wed) - 10 (Fri), 2023 / Lotte Hotel World, Seoul, Korea

Min J, Kim HW, Kim JS. Tuberculosis - Republic of Korea, 2021. Tuberc Respir Dis (Seoul). 2022.

7. Min J, Kim HW, Kang JY, Kim SK, Kim JW, Kim YH, et al. Comparison of different regimens with or without fluoroquinolone in isoniazid-resistant tuberculosis: A multicenter cohort study. PLoS One. 2022;17(8):e0273263.

8. Min J, Kim HW, Choi JY, Shin AY, Kang JY, Lee Y, et al. Latent Tuberculosis Cascade of Care Among Healthcare Workers: A Nationwide Cohort Analysis in Korea Between 2017 and 2018. J Korean Med Sci. 2022;37(20):e164.

9. Koo HK, Min J, Kim HW, Ko Y, Oh JY, Jeong YJ, et al. Cluster analysis categorizes five phenotypes of pulmonary tuberculosis. Sci Rep. 2022;12(1):10084.

10. Ko Y, Min J, Kim HW, Koo HK, Oh JY, Jeong YJ, et al. Time delays and risk factors in the management of patients with active pulmonary tuberculosis: nationwide cohort study. Sci Rep. 2022;12(1):11355.

11. Kim JS, Kim YH, Lee SH, Kim YH, Kim JW, Kang JY, et al. Early Bactericidal Activity of Delpazolid (LCB01-0371) in Patients with Pulmonary Tuberculosis. Antimicrob Agents Chemother. 2022;66(2):e0168421.

12. Kim HW, Park S, Min J, Sun J, Shin AY, Ha JH, et al. Hidden loss to follow-up among tuberculosis patients managed by public-private mix institutions in South Korea. Sci Rep. 2022;12(1):12362.

13. Kim HW, Min J, Choi JY, Shin AY, Myong JP, Lee Y, et al. Prevalence of latent tuberculosis infection among participants of the national LTBI screening program in South Korea - A problem of low coverage rate with current LTBI strategy. Front Public Health. 2022;10:1066269.

14. Kim HW, Kim KH, Shin AY, Choi JY, Ahn JH, Kim JS, et al. Investigating the appropriate adenosine deaminase cutoff value for the diagnosis of tuberculous pleural effusion in a country with decreasing TB burden. Sci Rep. 2022;12(1):7586.

15. Jeong YJ, Kang JY, Kim HW, Min J, Ko Y, Oh JY, et al. Association of Underlying Comorbidities and Sites of tuberculosis: an analysis using surveillance data. BMC Pulm Med. 2022;22(1):417.